Non-Hodgkin Lymphoma | Specialty

FDA Approval Sought for Loncastuximab Tesirine for Relapsed/Refractory DLBCL

September 22nd 2020

A biologics license application has been submitted to the FDA for loncastuximab tesirine for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.

Dr. Zonder on the ZUMA-2 and ZUMA-5 Trials in MCL and iNHL

September 22nd 2020

Jeffrey Zonder, MD, discusses the ZUMA-2 trial in mantle cell lymphoma and the ZUMA-5 trial in indolent non-Hodgkin lymphoma.

Dr. Pagel on the Utility of CAR T-Cell Therapy in Relapsed/Refractory DLBCL

September 22nd 2020

John M. Pagel, MD, PhD, discusses the utility of CAR T-cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

Dr. Welslau on the Rationale for the REFLECT Trial With Rituximab Biosimilar

September 22nd 2020

Manfred Welslau, MD, discusses the rationale of the prospective REFLECT trial with the rituximab biosimilar SDZ-RTX in patients with diffuse large B-cell lymphoma.

Dr. Seymour on the Kinase Selectivity of BTK Inhibitors in CLL

September 22nd 2020

Erlene Seymour, MD, discusses the kinase selectivity of BTK inhibitors in chronic lymphocytic leukemia.

Expert Perspectives in the Evolving Treatment Landscape of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

September 22nd 2020

Faculty debate the definitions of chemotherapy resistance, sensitivity, and refractoriness and discussed appropriate management strategies based on how patients would be classified in DLBCL.

Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

September 22nd 2020

Recent trials of novel therapies and therapeutic combinations have introduced promising options for the management of patients with relapsed or refractory diffuse large B-cell lymphoma.

Bruton Tyrosine Kinase Inhibitors in B-Cell Lymphomas

September 22nd 2020

Bruton tyrosine kinase (BTK) inhibitors play an important role in the therapeutic spectrum of B-cell lymphomas.

Treatment of R/R DLBCL: Beyond CAR T Therapy

September 22nd 2020

Phase 2B SADAL Trial in R/R DLBCL

September 22nd 2020

RE-MIND Study in R/R DLBCL

September 22nd 2020

L-MIND Study in R/R DLBCL

September 22nd 2020

CAR T in Transplant-Eligible and Transplant-Ineligible DLBCL

September 22nd 2020

Standard of Care for Relapsed/Refractory DLBCL

September 22nd 2020

Dr. Nowakowski on the Rationale of the ENGINE Trial in DLBCL

September 22nd 2020

Grzegorz S. Nowakowski, MD, discusses the rationale for the ongoing, randomized phase 3 ENGINE study in diffuse large B-cell lymphoma.

Dr. Hill on the SADAL Trial With Selinexor in DLBCL

September 22nd 2020

Brian T. Hill, MD, PhD, discusses the data from the SADAL trial that led to the FDA approval of selinexor for use in patients with diffuse large B-cell lymphoma.

Dr. Maddocks on Remaining Challenges in Follicular Lymphoma

September 22nd 2020

Kami J. Maddocks, MD, discusses remaining challenges in treating patients with follicular lymphoma.

Dr. Skarbnik on the Importance of Personalized Treatment for Follicular Lymphoma

September 19th 2020

Alan P. Z. Skarbnik, MD, discusses the importance of personalizing treatment for patients with follicular lymphoma.

Dr. Batlevi on Challenges Faced in Follicular Lymphoma Management

September 18th 2020

Connie L. Batlevi, MD, PhD, discusses challenges faced in the treatment of patients with follicular lymphoma.

Dr. Balzarotti on the Challenges of Treating Elderly DLBCL

September 18th 2020

Monica Balzarotti, MD, discusses the challenges of treating elderly patients with diffuse large B-cell lymphoma.